The following written comments were submitted to the Office of Disability Policy of the Social Security Administration (SSA) by IFFGD President, Ceciel T. Rooker, in response to Docket No. SSA-2017-0042 on September 23, 2019.

 

 

Thank you for your leadership at the Office of Disability Policy. The International Foundation for Gastrointestinal Disorders (IFFGD) is grateful for the opportunity to comment on the Social Security Administration’s Notice of Proposed Rulemaking revising the medical criteria for evaluating digestive disorders (Docket No. SSA–2017–0042).

The International Foundation for Gastrointestinal Disorders (IFFGD) is a registered nonprofit education and research organization dedicated to informing, assisting, and supporting people affected by gastrointestinal (GI) disorders. IFFGD works with patients, families, physicians, nurses, practitioners, investigators, regulators, employers, and others to broaden understanding about GI disorders, support and encourage research, and improve digestive health in adults and children.

Functional GI and motility disorders are the most common GI disorders in the general population. These disorders are classified by symptoms related to any combination of the following: motility disturbance, visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota, and altered central nervous system (CNS) processing. Some examples of functional GI and motility disorders are: dyspepsia, gastroparesis, irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), bowel incontinence, and cyclic vomiting syndrome.

IFFGD represents both adult and child patients from several of the communities affected by this NPRM, including those managing short bowel syndrome (SBS), malnutrition, digestive organ transplantations, esophageal stricture or stenosis, gastrointestinal hemorrhaging, and patients who require medical foods including supplemental daily enteral feeding via a gastrostomy.

Comments on Proposed Listing 5.08: Malnutrition due to any digestive disorder

With an increase in obesity rates, a malnourished individual with unintentional weight loss may not decrease to a BMI of <18kg/m2 as stated in the proposed listing 5.08. The proposed criteria of using BMI measurements to evaluate malnutrition may not be inclusive enough for our patient community. In 2015 T. Cederholm, et al. published a study where approximately 3000 European Society of Clinical Nutrition and Metabolism (ESPEN) members throughout the world graded their acceptance of valid malnutrition diagnosing criteria (1). As a result, ESPEN endorsed recommendations for increasing accuracy when diagnosing malnutrition. Without an accurate diagnosis, patients are unable to receive treatment necessary to ensure proper nutrient uptake. The ESPEN recommended Nutritional Risk Screening 2002 (NRS-2002), Mini Nutritional Assessment-Short Form (MNA-SF) and Malnutrition Universal Screening Tool (MUST) consider ranges of disease severity, recent unplanned weight loss, decreased dietary intake and other factors to determine malnutrition. Lack of nutrient intake or uptake is a result of many gastrointestinal disorders, in some cases leading to malnutrition. This article includes recommendations on measuring loss of BMI as well as other possible alternatives to ensure more accurate diagnosis of malnutrition. Please consider a more inclusive and extensive criteria for malnutrition evaluation.

Comments on Proposed Listing 5.07: Short Bowel Syndrome

We applaud the committee’s decision to expand the definition of Short Bowel Syndrome (SBS) to include patients with “any amount” of resection versus the “more than one half” as required previously. We agree that this is in line with the current research findings that patients with any amount of bowel removed will likely have nutritional needs above those in the healthy population. However, in a review by P. Jeppesen MD, PhD, it is highlighted that short bowel syndrome includes not only a range of retained intestinal length but also a range of dependency on parenteral nutrition (2). Patients with short bowel syndrome seek at least some independence from parenteral nutrition as a part of improving their quality of life. IFFGD’s patient community continually searches for ways to decrease dependency to parenteral nutrition as there is a high social burden being parenteral nutrition dependent. As a result, IFFGD proposes expanding the criteria of short bowel syndrome to support patients who are not completely parenteral nutrition dependent but will experience better quality of life if it is supplementary in some form. Additionally, medications are now available for patients with SBS to taper their dependency to parenteral nutrition. With successful therapy and tapering of medical nutrition, applicable patients may achieve independence. Requiring full dependency of daily parenteral nutrition prevents patients from retaining insurance coverage during their treatment time, making them unable to complete treatment.

 

References

1 - Cederholm, T., et al. “Diagnostic Criteria for Malnutrition – An ESPEN Consensus Statement.” Clinical Nutrition, vol. 34, no. 3, 2015, pp. 335–340., doi:10.1016/j.clnu.2015.03.001.

2 - Jeppesen, Palle B. “Spectrum of Short Bowel Syndrome in Adults.” Journal of Parenteral and Enteral Nutrition, vol. 38, no. 1_suppl, 2014, doi:10.1177/0148607114520994.

About IFFGD
Leadership
Nancy J. Norton, IFFGD Founder
Ceciel T. Rooker, IFFGD President
Advisory Board
Officers and Board of Directors
Editorial Board Members
Our Mission
Awareness Activities & Accomplishments
Public Education & Awareness
Professional Education & Awareness
Year in Review
-2017
-2015
-2014
-2012/2013
Advocacy Activities
Legislative Successes
FGIMD Act (Functional Gastrointestinal and Motility Disorders Research Enhancement Act)
Congressional Testimony
FISCAL YEAR 2020
FISCAL YEAR 2019
FISCAL YEAR 2013
FISCAL YEAR 2012
FISCAL YEAR 2010
FISCAL YEAR 2009
FISCAL YEAR 2008
FISCAL YEAR 2007
FISCAL YEAR 2006
FISCAL YEAR 2005
FISCAL YEAR 2004
FISCAL YEAR 2003
FISCAL YEAR 2016
FDA and Other Testimony
Written Comments to FDA December 30, 2019
Written Comments to FDA October 15, 2019
Written Comments to SSA September 23, 2019
Written comments to FDA April 30, 2019
Written Comments to SSA February 15, 2019
Written Comments to HHS February 5, 2019
Written Comments to DoD December 13, 2018
Written Comments to FDA October 18, 2018
Written Comments to FDA October 17, 2018
Written Presentation to FDA September 12, 2017
Written Comments to FDA June 29, 2015
Oral Comments to FDA May 11, 2015
Comments to FDA July 16th, 2014
Written Comments to Noridian October 24, 2013
Testimony to FDA October 25, 2012
Testimony to FDA September 12, 2012
Testimony to FDA December 13, 2011
Testimony to FDA December 2, 2010
Testimony to FDA April 23, 2002
Comments to FDA November 9, 2000
Testimony to FDA June 27, 2000
Testimony to FDA June 26, 2000
Capitol Hill Advocacy Day
National Institutes of Health (NIH)
CDC
FDA
Research
IFFGD Research Awards
IFFGD Symposium reports
2013 Professional Symposium
10th Symposium Report
10th Symposium Audio Recordings
More from the 10th Symposium on FGIDs
2011 Professional Symposium
9th Symposium Report
2009 Professional Symposium
2007 Professional Symposium
7th Symposium Report
2005 Professional Symposium
6th Symposium Report
2003 Professional Symposium
5th Symposium Report
2002 Conference - Advancing the Treatment of Incontinence
Funding
Corporate Support
Our Research Funding Needs
IFFGD Standards for Collaboration
Industry Council
Code of Ethics
Contact Us
Media Contact
Donation

Advocacy Effort

capital hill day s

Involvement in Shaping National Health Care Policy

IFFGD is a voice on Capital Hill working with the digestive health community.

Advocacy Activities, Legislative & Regulatory

Legislative Successes

Congressional Testimony